Updated:
QLT
QLT — pharmaceutical royalty firm created by Visudyne, now operating as a passive capital vehicle with North American ties.
QLT
QLT was founded in the 1980s and originally concentrated on photodynamic therapy. The company developed Visudyne, a treatment for wet age-related macular degeneration, in collaboration with Novartis. Wealth originated from pharmaceutical innovation and subsequent royalty streams. After selling its commercial operations, QLT pivoted to a royalty monetization strategy. The firm's portfolio includes licensed therapies and milestone-based assets. Its geographic footprint spans North America, with former presence in Europe. The company has discontinued active product development and now focuses on managing existing intellectual property. No recent team expansions or new fund vehicles are publicly documented. QLT maintains legacy partnerships with pharmaceutical partners but does not disclose current deployment or AUM figures. The firm's operational structure appears minimalist, consisting of a small team managing passive cash flows. QLT's structural differentiator is its transition from a development-stage biotech to a royalty company — a rare pivot that aligns it more with a passive asset holding vehicle than an active asset manager or family office.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed (Altss estimate)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Vancouver, Canada
Sector focus
Frequently asked questions
What is QLT's current business model?
QLT shifted from drug development to a royalty and licensing model after selling its commercial operations. It now generates revenue from milestone payments and royalty streams from therapies it previously developed or in-licensed (public record). The firm does not actively invest in new R&D.
Does QLT still have a Vancouver office?
Yes, QLT maintains an office in Vancouver, British Columbia, alongside a New York headquarters (per the firm's official records). The firm also had a European presence historically, but that appears wound down.
Who makes investment decisions at QLT?
Investment decisions are made by QLT's executive team, which has not been publicly named in recent years. The firm's public filings indicate a small leadership group focused on royalty asset management and financial oversight.
Is QLT considered a family office?
No — QLT is a publicly held asset manager that operates as a royalty corporation. It does not have the structure or mandate of a family office, despite once being categorized by some data vendors as such. It lacks family-based wealth origin or multi-generational capital management.
What therapy platforms does QLT hold royalties on?
QLT's primary known royalty stream was from Visudyne (verteporfin) for wet AMD, licensed to Novartis (public record). Other legacy assets include dermatology treatments and photodynamic therapy compounds, though specific current holdings are not publicly updated.
Does QLT invest in new biotechnology companies?
No — QLT no longer makes active investments or product development. Its post-sale model focuses on managing existing royalty and licensing agreements without deploying capital into new ventures or partnerships.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: